Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), plaque Psoriasis (PsO) and paediatric plaque PsO. MedDRA version: 14.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders
Conditions
Interventions
Product Name: SB4 (etanercept biosimilar)
Product Code: SB4
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ETANERCEPT
CAS Number: 185243-69-0
Current Sponsor co
Sponsors
Samsung Bioepis Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Are male or female aged 18–75 years at the time of signing the consent form. 2. Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria 3. Have more than or equal to six swollen joints, more than or equal to six tender joints (from the 66/68 joint count system) at Screening and Randomisation and either erythrocyte sedimentation rate (Westergren) = 28 mm/h or serum C-reactive protein = 1.0 mg/dL at Screening. 4. Must have been treated with MTX for at least 6 months prior to Randomisation and on a stable dose of MTX 10–25 mg/week given orally or parenterally for at least 4 weeks prior to Screening. 5. Female subjects who are not pregnant or nursing at Screening and who are not planning to become pregnant from Screening until 2 months after the last dose of investigational product (IP). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 438 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60
Exclusion criteria
Exclusion criteria: 1. Have been treated previously with any biological agents including any tumour necrosis factor inhibitor. 2. Have a known hypersensitivity to human immunoglobulin proteins or other components of Enbrel or SB4. 3. Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus. 4. Have a current diagnosis of active tuberculosis 5. Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation. 6. Have any of the following conditions a. Other inflammatory or rheumatic diseases. b. History of any malignancy within the previous 5 years prior to Screening c. History of lymphoproliferative disease including lymphoma. d. History of congestive heart failure e. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound). f History of demyelinating disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to demonstrate the equivalence of SB4 to Enbrel® at Week 24, in terms of American College of Rheumatology 20% response criteria (ACR 20) response rate in subjects with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.;Secondary Objective: The secondary objectives are: ? To evaluate efficacy of SB4 compared to Enbrel using relevant efficacy endpoints other than ACR 20 at Week 24 in subjects with moderate to severe RA despite MTX therapy ? To evaluate safety and tolerability of SB4 compared to Enbrel in subjects with moderate to severe RA despite MTX therapy ? To evaluate pharmacokinetics of SB4 compared to Enbrel in subjects with moderate to severe RA despite MTX therapy ? To evaluate immunogenicity of SB4 compared to Enbrel in subjects with moderate to severe RA despite MTX therapy;Primary end point(s): The primary endpoint for the study is the ACR 20 response at Week 24;Timepoint(s) of evaluation of this end point: Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): The secondary efficacy endpoints are: ? The ACR 20 response at Week 52 ? The ACR 50 response and ACR 70 response at Week 24 and Week 52 ? The numeric index of the ACR response (ACR-N) at Week 24 and Week 52 ? The area under the curve (AUC) of ACR-N up to Week 24 ? The disease activity score based on a 28 joint count (DAS28 score) at Week 24 and Week 52 ? The European League Against Rheumatism response at Week 24 and Week 52 ? The AUC of the change in DAS28 from Baseline up to Week 24? Major clinical response (ACR 70 response for 6 consecutive months) at Week 52 ? Change from baseline in modified Total Sharp Score at Week 52;Timepoint(s) of evaluation of this end point: ? The ACR 20 response at Week 52 ? The ACR 50 response and ACR 70 response at Week 24 and Week 52 ? The numeric index of the ACR response (ACR-N) at Week 24 and Week 52 ? The area under the curve (AUC) of ACR-N up to Week 24 ? The disease activity score based on a 28 joint count (DAS28 score) at Week 24 and Week 52 ? The European League Against Rheumatism response at Week 24 and Week 52 ? The AUC of the change in DAS28 from Baseline up to Week 24? Major clinical response (ACR 70 response for 6 consecutive months) at Week 52 ? Change from baseline in modified Total Sharp Score at Week 52 | — |
Countries
Bulgaria, Colombia, Czech Republic, Hungary, India, Korea, Republic of, Lithuania, Mexico, Poland, Ukraine, United Kingdom
Contacts
Public ContactQuintiles Contact Centre
Quintiles Limited
Outcome results
None listed